Lawmakers Urge Patent Office to Address Rule Loopholes Extending Pharma Monopolies

Federal patent officials are facing pressure from lawmakers to amend regulations they say allow pharmaceutical companies to prolong their patent rights beyond the intended period. The current standards have raised concerns about drug companies maintaining monopolies on drug patents, thereby affecting market competition and drug prices. For more detailed information, the full discussion is available at Law360.